Why the study?
What is the incidence and what are the clinical characteristics of severe upper gastrointestinal bleeding requiring endoscopic hemostasis in patients on antithrombotic therapy?
Observational (n=978)
No
What is the incidence and what are the clinical characteristics of severe upper gastrointestinal bleeding requiring endoscopic hemostasis in patients on antithrombotic therapy?
Answers are grounded in this paper and cite their sources.
Severe upper gastrointestinal bleeding requiring endoscopic hemostasis occurs in 0.21% of patients on antithrombotic therapy, with warfarin carrying the highest risk and gastric ulcers being the most common cause.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kwak et al. (2017) conducted an observational in Severe upper gastrointestinal bleeding (UGIB) (n=978). Antithrombotic therapy (ATT) vs. No antithrombotic therapy was evaluated on Incidence of severe UGIB requiring endoscopic hemostasis.
Synapse has enriched 10 related papers. Consider them for comparative context: